36. 表皮水疱症 Epidermolysis bullosa Clinical trials / Disease details


臨床試験数 : 160 薬物数 : 195 - (DrugBank : 47) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 124

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-003890-91-PL
(EUCTR)
29/09/202013/11/2018Treatment of wound in the course of Epidermolysis Bullosa, chronic venous leg ulceration and thermal injury by biological dressing made of mesynchemal stem cells seeded on acellular human skin.The development of innovative advanced therapy medicinal product (biological dressing of the human race) in the treatment of Epidermolysis Bullosa (EB) and other chronic wounds. BIOOPA dressing will be used in the treatment of wounds in the course of Epidermolysis Bullosa, chronic venous leg ulceration and thermal injury (second degree burn).
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: BIOOPA dressing
INN or Proposed INN: Human Allogeneic WJ-MSCs
Other descriptive name: WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS
Medical University of WarsawNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 1;Phase 2Poland
2JPRN-UMIN000028366
2017/06/2125/07/2017A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients.A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients. - A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients. dystrophic epidermolysis bullosaISN001, the sheet containing allogenic adipose derived mesenchymal stromal cells (1000000/sheet), is applied to the lesion(s) once a week up to 8 timesIshin Pharmaceutical Co. Ltd.NULLComplete: follow-up complete6years-old70years-oldMale and Female5Phase 1,2Japan
3NCT02323789
(ClinicalTrials.gov)
June 201518/12/2014Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis BullosaA Phase I/II Study Evaluating Allogeneic Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaDrug: Mesenchymal stromal cellsKing's College LondonNULLActive, not recruiting18 Years65 YearsAll10Phase 1/Phase 2United Kingdom
4EUCTR2014-004500-30-GB
(EUCTR)
13/02/201522/12/2014A prospective phase I/II study to evaluate the use of mesenchymal stromal (stem) cells for the treatment of skin disease in adults with recessive dystrophic epidermolysis bullosa A phase I/II study evaluating allogeneic mesenchymal stromal cells in adults with recessive dystrophic epidermolysis bullosa - ADSTEM Recessive dystrophic epidermolysis bullosa;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Product Name: Allogeneic mesenchymal stromal cells
Product Code: TC-MSC
King's College LondonGuy's and St Thomas NHS Foundation TrustNot Recruiting Female: yes
Male: yes
10 Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
5EUCTR2012-000605-72-NL
(EUCTR)
06/02/201412/08/2013Stem cell transplantation with cord blood and mesenchymal stem cells after reduced intensity conditioning for severe forms of the blistering disease epidermolysis bullosaUnrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa - CB+MSCforEB The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB.;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Product Name: TC-MSC
INN or Proposed INN: Mesenchymal stromal cells
Trade Name: Busilvex
Trade Name: Fludarabine
Product Name: FLudarabine
Trade Name: THYMOGLOBULINE
Product Name: Thymoglobuline
Universitair Medisch Centrum UtrechtNULLNot RecruitingFemale: yes
Male: yes
11Phase 2Netherlands
6EUCTR2012-001394-87-GB
(EUCTR)
16/11/201222/08/2012A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa. A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa. - EBSTEM Recessive Dystrophic Epidermolysis Bullosa
MedDRA version: 17.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Allogenic mesenchymal stromal cells
Product Code: TC-MSC
King's College LondonNULLNot RecruitingFemale: yes
Male: yes
10Phase 1;Phase 2United Kingdom
7EUCTR2020-002936-55-CZ
(EUCTR)
03/08/2020Safety and Efficacy of Mesenchymal Stromal Cells Derived from Adipose Tissue of Non-related Donors in Patients with The Butterfly Disease: Clinical Trial Phase I/IISafety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells in Patients with Epidermolysis Bullosa: Clinical Trial Phase I/II - MSC-EB Epidermolysis bullosa congenita;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Product Name: allogeneic adipose tissue-derived MSC
INN or Proposed INN: Human allogeneic adipose tissue-derived mesenchymal stem cells expanded
Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED
Masarykova univerzitaNULLNAFemale: yes
Male: yes
15Phase 1;Phase 2Czech Republic